1 / 22

Why molecular modeling?

Why molecular modeling?. Experiments are currently impossible Eg Alzheimer’s Disease & protein aggregation We need more detail Polymerase, protein folding We need results faster Eg small molecule drug design. Challenges. Computer power New hardware, new algorithms Experiments to test

hieu
Télécharger la présentation

Why molecular modeling?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Why molecular modeling? • Experiments are currently impossible • Eg Alzheimer’s Disease & protein aggregation • We need more detail • Polymerase, protein folding • We need results faster • Eg small molecule drug design

  2. Challenges • Computer power • New hardware, new algorithms • Experiments to test • Experimentalists to become more familiar with computational methods

  3. Recommendations • How to accelerate acceptance of modeling • Infrastructure • Education • More experiments, more systematically

  4. Issues • The current perception of modeling in the biomedical and clinical research community, what needs to change to encourage more acceptance? • Future biomedical and clinical applications for models, based on current success stories, things that couldn't be solved w/o models, time to cure – e.g. comparative effectiveness research

  5. 100000 TZ2 tu BBA5 (GB/SA) 10000 BBA5 (TIP3P) TZ2 tf villin (TIP3P) villin (GB/SA) Trp cage simulation (ns) 1000 alpha helix (Fs peptide) 100 PPA 10 1.0106 y = 0.7853x 2 R = 0.9684 1 1 10 100 1000 10000 100000 experiment (ns) Quantitative prediction of experiments • Important to us: • Validation • Model quality is still a challenge • Important for acceptance • Natural way to show a model’s value • Surprise: These ideas are not well accepted

  6. Bond vibration Isomer- ation Water dynamics Helix forms Fastprotein folding Slowconf change proteinoligomerization 10-15 femto 10-12 pico 10-9 nano 10-6 micro 10-3 milli 100 seconds 103 seconds MD step long MD run where we’d love to be Major challenge at the atomic scale: long timescales • Fundamental problem for simulation • typical fast processor can simulate ~1 ns/day • a second of dynamics requires 1 billion CPU-days • even a millisecond is hard (million CPU-days) • however, scaling is hard -- not easy to break the problem down into a billion pieces

  7. What can be done about this challenge?Two key advances in simulation methodology • New computational paradigms • Specialized hardware (GPU, Larrabee, Anton) • 100x to 1000x over a CPU • Cloud/Grid/HPC computing • Large unmet needs for computing resources • Enables greater data and model sharing • New algorithms, new approaches needed ATI 4870 (1000 GFlops peak, ~$200 + of a cost computer) For example: Folding@home ~400,000 CPUs ~8 petaflops total performance

  8. NTL9 λ-repressor Solution: must combining technologies.Millisecond timescale today, seconds next seconds milliseconds villin microseconds

  9. Natural areas to apply computational methods (especially when combined with HPC) • Alzheimer’s Disease • Small molecule inhibitors • Nature of misfolding • Viral infection • Critical mutants • Biophysical mechanism • Why are these natural areas to tackle with simulation? • experiments are extremely challenging • Simulations are easier in some ways Direct simulation ofAlzheimer’s Disease Direct simulation of Viral infection

  10. “Useful” testable hypotheses WT after 1 day mutant after 14 days mutant after 30 days • Beyond validation • Combine validation and acceptance of models • Most useful for us if tests are themselves key results 200nm 100nm 100nm

  11. For discussion • The current perception of modeling in the biomedical and clinical research community, what needs to change to encourage more acceptance? • going “over the top” in terms of connection to experiment • education on methods: many experimentalists can’t judge model quality • looking for experimentalists who need computational help

  12. For discussion • Role of High Performance Computing (HPC) in biomedical computation • insatiable need, challenge in accessing • common approaches between scales will help in many ways (advances from one scale and transform another) • Additional traditional supercomputer resources • Ways to share distributed resources like Folding@home more broadly could transform several fields

  13. Summary • a) How modeling has impacted various research fields (success stories and mechanisms)? Is it the onus on modelers to prove that their models are useful to someone else? • b) To what extent has the broader research communities accepted modeling as a critical tool for driving research or policy (what has worked and what hasn't worked)? • c) In what ways can modeling further impact the broader research communities (how far can we go)? • d) What are the major challenges to overcome (how do we get there)?

  14. How modeling has impacted various research fields? • Culture exists in chemistry, natural impact • Biologists becoming more physical

  15. Has the research communities accepted modeling as a critical tool for driving research • Interest

  16. How modeling has impacted various research fields? • Culture exists in chemistry, natural impact • Biologists becoming more physical

  17. Other success stories • computational drug design • Several labs and biotechs have examples • computation is not “all or nothing” but has become well integrated (almost silently) into many areas of drug design • protein design • inverse of protein folding: predict sequence from structure • numerous examples of successes • novel catalysts • SARS computational effort • also why failed -- push from failures • models too simple • sampling too little • many failures derive from too little computational power to achieve the desired goals

  18. Broader impacts • Pharmaceutical company interest • specific collaborations (Acumen, Vertex, Numerate) • simulations driving experiments • understand limitations

  19. A statistical approach to simulation:Markov State Models • Define states in the conformation space • Define transition probabilities between states • Utilize a large number of statistical sampling methods to do this very efficiently • Yields a full kinetic/thermodyanmic model of the original system

More Related